DNMT1-maintained hypermethylation of Krüppel-like factor 5 involves in the progression of clear cell renal cell...

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Clear cell renal cell carcinoma (ccRCC) is a major subtype of renal cell carcinoma (RCC) resistant to conventional therapies.
• Identifying effective therapeutic targets for ccRCC remains a significant challenge.
• Krüppel-like factor 5 (KLF5) plays varied roles in different cancers.

Purpose of the Study:

• To investigate the role of KLF5 in ccRCC.
• To explore the relationship between KLF5, DNA methylation, and ccRCC progression.
• To evaluate the therapeutic potential of modulating KLF5 expression in ccRCC.

Main Methods:

• Analysis of Cancer Genome Atlas (TCGA) data sets for KLF5 expression and patient prognosis.
• Investigation of KLF5 gene methylation status and its regulation by DNA methyltransferase 1 (DNMT1).
• In vitro and in vivo experiments assessing the effects of KLF5 expression and 5-Aza-CdR treatment on ccRCC cells.

Main Results:

• KLF5 expression is suppressed in ccRCC, and higher KLF5 levels correlate with better prognosis.
• KLF5 genomic loci are hypermethylated, and DNMT1 suppression or 5-Aza-CdR treatment restores KLF5 expression.
• Ectopic KLF5 expression inhibits ccRCC cell proliferation, migration, invasion, and metastasis.
• 5-Aza-CdR suppresses ccRCC growth by inducing KLF5 expression, an effect abolished by KLF5 knockdown.

Conclusions:

• KLF5 functions as a tumor suppressor in ccRCC.
• Epigenetic silencing of KLF5 via hypermethylation contributes to ccRCC development.
• 5-Aza-CdR, a DNMT inhibitor, shows therapeutic potential for ccRCC by reactivating KLF5.